Original Article

You have free access to this content

Divergent cancer pathways for early-onset and late-onset cutaneous malignant melanoma†‡

  1. William F. Anderson MD, MPH1,§,*,
  2. Ruth M. Pfeiffer PhD1,
  3. Margaret A. Tucker MD2,
  4. Philip S. Rosenberg PhD1

Article first published online: 17 JUN 2009

DOI: 10.1002/cncr.24481

Issue

Cancer

Cancer

Volume 115, Issue 18, pages 4176–4185, 15 September 2009

Additional Information

How to Cite

Anderson, W. F., Pfeiffer, R. M., Tucker, M. A. and Rosenberg, P. S. (2009), Divergent cancer pathways for early-onset and late-onset cutaneous malignant melanoma. Cancer, 115: 4176–4185. doi: 10.1002/cncr.24481

Author Information

  1. 1

    Biostatistics Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bethesda, Maryland

  2. 2

    Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bethesda, Maryland

  1. §

    Fax: (301) 402-0081

*Biostatistics Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Institutes of Health, National Cancer Institute, EPS, Room 8036, 6120 Executive Boulevard, Bethesda, MD 20892-7244

  1. †

    We thank the reviewers for helpful comments, which improved the content of this article.

  2. ‡

    This article is US Government work and, as such, is in the public domain in the United States of America.

Publication History

  1. Issue published online: 4 SEP 2009
  2. Article first published online: 17 JUN 2009
  3. Manuscript Accepted: 5 FEB 2009
  4. Manuscript Revised: 2 FEB 2009
  5. Manuscript Received: 8 DEC 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (408K)

References

  • 1
    Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006; 24: 4340-4346.
  • 2
    Fecher LA, Cummings SD, Keefe MJ, Alani RM. Toward a molecular classification of melanoma. J Clin Oncol. 2007; 25: 1606-1620.
  • 3
    Elwood JM, Lee JA, Walter SD, Mo T, Green AE. Relationship of melanoma and other skin cancer mortality to latitude and ultraviolet radiation in the United States and Canada. Int J Epidemiol. 1974; 3: 325-332.
  • 4
    Mack TM, Floderus B. Malignant melanoma risk by nativity, place of residence at diagnosis, and age at migration. Cancer Causes Control. 1991; 2: 401-411.
  • 5
    Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer. 1997; 73: 198-203.
    Direct Link:
  • 6
    Hakansson N, Floderus B, Gustavsson P, Feychting M, Hallin N. Occupational sunlight exposure and cancer incidence among Swedish construction workers. Epidemiology. 2001; 12: 552-557.
  • 7
    Bulliard JL. Site-specific risk of cutaneous malignant melanoma and pattern of sun exposure in New Zealand. Int J Cancer. 2000; 85: 627-632.
    Direct Link:
  • 8
    Fears TR, Scotto J, Schneiderman MA. Mathematical models of age and ultraviolet effects on the incidence of skin cancer among whites in the United States. Am J Epidemiol. 1977; 105: 420-427.
  • 9
    Siskind V, Whiteman DC, Aitken JF, Martin NG, Green AC. An analysis of risk factors for cutaneous melanoma by anatomical site (Australia). Cancer Causes Control. 2005; 16: 193-199.
  • 10
    Tucker MA. Is sunlight important to melanoma causation? Cancer Epidemiol Biomarkers Prev. 2008; 17: 467-468.
  • 11
    Thompson WD. Effect modification and the limits of biological inference from epidemiologic data. J Clin Epidemiol. 1991; 44: 221-232.
  • 12
    Anderson WF, Rosenberg PS, Menashe I, Mitani A, Pfeiffer RM. Age-related crossover in breast cancer incidence rates between black and white ethnic groups. J Natl Cancer Inst. 2008; 100: 1804-1814.
  • 13
    National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program. SEER Program, SEER*Stat Database: Incidence-SEER 9 Registries, limited-use, based on the November 2006 submission (1992-2004). Bethesda, Md: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; 2007. Available at: http://www.seer.cancer.gov Accessed on February 1, 2009.
  • 14
    World Health Organization. International Classification of Diseases for Oncology. 3rd ed. US Interim Version 2000. Geneva, Switzerland: World Health Organization; 2000.
  • 15
    Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics. 1985; 41: 361-372.
  • 16
    Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End results database. Breast Cancer Res Treat. 2002; 76: 27-36.
  • 17
    Anderson WF, Pfeiffer RM, Dores GM, Sherman ME. Comparison of age frequency distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev. 2006; 15: 1899-1905.
  • 18
    Pfeiffer RM, Carroll RJ, Wheeler W, Whitby D, Mbulaiteye S. Combining assays for estimating prevalence of human herpes virus 8 infection using multivariate mixture models. Biostatistics. 2008; 9: 137-151.
  • 19
    Holford TR. The estimation of age, period and cohort effects for vital rates. Biometrics. 1983; 39: 311-324.
  • 20
    Akaike H. Information theory and an extension of the maximum likelihood principle. In: PetrovB, CsakiF, eds. Proceedings of the Second International Symposium on Information Theory. Budapest, Hungary: Akademiai Kiado; 1973: 267-281.
  • 21
    Mishima Y. Melanocytic and nevocytic malignant melanomas. Cellular and subcellular differentiation. Cancer. 1967; 20: 632-649.
    Direct Link:
  • 22
    Whiteman DC, Watt P, Purdie DM, Hughes MC, Hayward NK, Green AC. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst. 2003; 95: 806-812.
  • 23
    Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969; 29: 705-727.
  • 24
    Clark WH Jr, Ainsworth AM, Bernardino EA, Yang CH, Mihm CM Jr, Reed RJ. The developmental biology of primary human malignant melanomas. Semin Oncol. 1975; 2: 83-103.
  • 25
    McGovern VJ, Cochran AJ, Van der Esch EP, Little JH, MacLennan R. The classification of malignant melanoma, its histological reporting and registration: a revision of the 1972 Sydney classification. Pathology (Phila). 1986; 18: 12-21.
  • 26
    McGovern VJ. The classification of melanoma and its relationship with prognosis. Pathology (Phila). 1970; 2: 85-98.
  • 27
    Ackerman AB. Malignant melanoma: a unifying concept. Hum Pathol. 1980; 11: 591-595.
  • 28
    Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19: 3635-3648.
  • 29
    Whiteman DC, Parsons PG, Green AC. p53 Expression and risk factors for cutaneous melanoma: a case-control study. Int J Cancer. 1998; 77: 843-848.
    Direct Link:
  • 30
    Purdue MP, From L, Kahn HJ, et al. Etiologic factors associated with p53 immunostaining in cutaneous malignant melanoma. Int J Cancer. 2005; 117: 486-493.
    Direct Link:
  • 31
    Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003; 95: 1878-1890.
  • 32
    Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005; 353: 2135-2147.
  • 33
    Landi MT, Bauer J, Pfeiffer RM, et al. MC1R germline variants confer risk for BRAF-mutant melanoma. Science. 2006; 313: 521-522.
  • 34
    Cohen Y, Rosenbaum E, Begum S, et al. Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. Clin Cancer Res. 2004; 10: 3444-3447.
  • 35
    Lachiewicz AM, Berwick M, Wiggins CL, Thomas NE. Epidemiologic support for melanoma heterogeneity using the Surveillance, Epidemiology, and End Results Program. J Invest Dermatol. 2008; 128: 243-245.
View Full Article (HTML) Get PDF (408K)